Principal Financial Group Inc. Buys 32,564 Shares of Pfizer Inc. $PFE

Principal Financial Group Inc. grew its stake in Pfizer Inc. (NYSE:PFE) by 0.5% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 6,339,372 shares of the biopharmaceutical company’s stock after buying an additional 32,564 shares during the period. Principal Financial Group Inc.’s holdings in Pfizer were worth $178,010,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. Horizon Financial Services LLC lifted its position in shares of Pfizer by 174.8% in the 4th quarter. Horizon Financial Services LLC now owns 1,014 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 645 shares during the period. Godfrey Financial Associates Inc. bought a new stake in Pfizer during the fourth quarter valued at $26,000. YANKCOM Partnership acquired a new stake in Pfizer during the 4th quarter worth about $28,000. HFM Investment Advisors LLC raised its position in shares of Pfizer by 61.0% in the 4th quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company’s stock worth $28,000 after acquiring an additional 427 shares in the last quarter. Finally, Evolution Wealth Management Inc. raised its position in shares of Pfizer by 132.2% in the 1st quarter. Evolution Wealth Management Inc. now owns 994 shares of the biopharmaceutical company’s stock worth $28,000 after acquiring an additional 566 shares in the last quarter. 68.36% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities research analysts recently commented on PFE shares. Cantor Fitzgerald restated a “neutral” rating and set a $27.00 target price on shares of Pfizer in a research report on Monday, July 6th. UBS Group reiterated a “neutral” rating and issued a $27.00 target price on shares of Pfizer in a report on Wednesday, May 27th. Royal Bank Of Canada upgraded Pfizer from an “underperform” rating to a “sector perform” rating and set a $25.00 price target on the stock in a report on Tuesday, June 9th. HSBC downgraded shares of Pfizer from a “buy” rating to a “hold” rating and reduced their price objective for the stock from $32.00 to $28.00 in a research report on Monday, July 6th. Finally, Weiss Ratings upgraded shares of Pfizer from a “hold (c-)” rating to a “hold (c)” rating in a research note on Wednesday, May 6th. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, fourteen have assigned a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $28.50.

More Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Analyst coverage remains supportive, even after some modest price-target cuts. BMO kept an outperform rating and Guggenheim maintained a buy, suggesting Wall Street still sees upside from current levels. Benzinga analyst update
• Positive Sentiment: Pfizer’s oncology franchise is in focus ahead of Q2 results, with growth from key cancer drugs, biosimilars, and pipeline updates potentially helping offset declines in older medicines. Zacks oncology outlook
• Positive Sentiment: Investors are also encouraged by the long-term case for Pfizer’s Seagen integration, which some analysts argue could improve oncology growth and create durable value versus peers like Amgen. 247WallSt Pfizer vs. Amgen
• Neutral Sentiment: Pfizer’s dividend yield remains unusually high at about 7.1%, which may attract income investors, but it also raises questions about whether the payout reflects slower growth expectations. Motley Fool dividend article
• Negative Sentiment: Near-term earnings expectations are soft, with Wall Street looking for a double-digit decline in profit in the next quarterly report, reinforcing concerns about pressure on Pfizer’s core business. Barchart earnings preview
• Negative Sentiment: Drug-pricing headlines tied to the Trump administration are adding policy uncertainty across big pharma, including Pfizer, even though pipeline strength may ultimately matter more. Motley Fool drug-pricing article

Pfizer Stock Down 1.0%

PFE stock opened at $24.24 on Wednesday. The stock’s 50 day simple moving average is $25.28 and its 200 day simple moving average is $26.18. The company has a market cap of $138.17 billion, a P/E ratio of 18.51 and a beta of 0.35. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.94 and a current ratio of 1.25. Pfizer Inc. has a fifty-two week low of $23.11 and a fifty-two week high of $28.75.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, May 5th. The biopharmaceutical company reported $0.75 EPS for the quarter, beating analysts’ consensus estimates of $0.72 by $0.03. The firm had revenue of $14.45 billion during the quarter, compared to analysts’ expectations of $13.84 billion. Pfizer had a return on equity of 19.44% and a net margin of 11.83%.The company’s revenue for the quarter was up 5.4% compared to the same quarter last year. During the same quarter last year, the firm posted $0.92 earnings per share. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, research analysts expect that Pfizer Inc. will post 2.96 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Friday, July 24th will be given a $0.43 dividend. The ex-dividend date of this dividend is Friday, July 24th. This represents a $1.72 annualized dividend and a yield of 7.1%. Pfizer’s dividend payout ratio (DPR) is presently 131.30%.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.